Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell)

Subscribe to Selected New Research on Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

209 relevant articles (6 outcomes, 17 trials/studies) found for this Disease

Description: A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.

Also Known As:

Leukemia, Pre B Cell; Pre B-ALL; Pre-B ALL; Precursor B-Cell Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Lymphoma; Leukemias, Pre-B-Cell; Pre B ALL; Pre B Cell Leukemia; Pre-B-Cell Leukemias; Precursor B Cell Lymphoblastic Leukemia; Precursor B Cell Lymphoblastic Leukemia Lymphoma; Precursor B Cell Lymphoblastic Lymphoma; Leukemia, Pre-B-Cell; Pre-B-Cell Leukemia

Relationship Network

Disease Context: Research Results

Neoplasms: 415397

Neoplasms by Histologic Type: 1

Leukemia: 33478

Lymphoid Leukemia: 1273

Precursor Cell Lymphoblastic Leukemia-Lymphoma: 8242

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: 209

Hemic and Lymphatic Diseases

Lymphatic Diseases: 1961

Lymphoproliferative Disorders: 2359

Lymphoid Leukemia: 1273

Precursor Cell Lymphoblastic Leukemia-Lymphoma: 8242

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: 209

Immune System Diseases: 1319

Immunoproliferative Disorders: 26

Lymphoproliferative Disorders: 2359

Lymphoid Leukemia: 1273

Precursor Cell Lymphoblastic Leukemia-Lymphoma: 8242

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: 209

Related Diseases

1.	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
2.	Leukemia
3.	Genetic Translocation (Chromosomal Translocation)
4.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
5.	Neoplasms (Cancer)

Experts

1.	Muroi, Kazuo: 1 article (02/2008)
2.	Kannagi, Reiji: 1 article (02/2008)
3.	Nonomura, Chizu: 1 article (02/2008)
4.	Mitsunaga, Kanae: 1 article (02/2008)
5.	Fujimoto, Junichiro: 1 article (02/2008)
6.	Kiyokawa, Nobutaka: 1 article (02/2008)
7.	Furukawa, Yusuke: 1 article (02/2008)
8.	Kanamori, Akiko: 1 article (02/2008)
9.	Ozaki, Hidenori: 1 article (02/2008)
10.	Kikuchi, Jiro: 1 article (02/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Precursor B-Cell Lymphoblastic Leukemia-Lymphoma:

1.	Immunotoxins (Immunotoxin)IBA 06/15/1992 - "B43-PAP plus CPA was superior to either the immunotoxin or drug alone, and combined immunochemotherapy markedly improved the event-free survival (EFS) of SCID mice challenged with NALM-6-UM1 pre-B ALL cells. " 06/01/1995 - "We used a SCID mouse model of aggressive human pre-B ALL to evaluate the in vivo anti-leukemic efficacy of the J3-109-PAP immunotoxin. " 05/01/1992 - "We used this SCID mouse model of aggressive human pre-B ALL to evaluate the in vivo antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin. " 06/15/1992 - "We used this SCID mouse model of human pre-B ALL to evaluate and compare, in a total of 434 SCID mice, the antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin and cyclophosphamide (CPA) as individual reagents and as combined immunochemotherapeutic regimens. " Order ALL the reference details at left...
2.	rituximab (Mabthera)FDA Link 01/01/2007 - "Here we describe a pre-B-ALL patient with therapy refractory cGVHD who relapsed only one month after receiving Rituximab therapy for cGVHD. " 01/01/2006 - "This case report describes the use of Rituximab for in vivo purging (by intravenous infusion) in a 12 years old boy with second remission of pre-B ALL. " 10/01/2006 - "We studied 61 CD20- B-cell lymphomas, including 29 cases of precursor B-cell lymphoblastic leukemia/lymphoblastic lymphoma (B-ALL/B-LBL), 25 cases of CD20- recurrent mature B-cell lymphoma after rituximab therapy, and 7 cases of CD20- diffuse large B cell lymphoma (DLBCL). " Order ALL the reference details at left...
3.	Prednisone (Sone)FDA LinkGeneric 09/17/1997 - "The current consensus is as follows: About 20% of children with ALL can be defined as high-risk patients by criteria such as t(9;22), t(4;11), no complete remission at day 42, poor prednisone response, and T-immunophenotype or pre-pre B-ALL, myeloid markers or more than 100,000 white blood cells/microliter. " Order ALL the reference details at left...
4.	Indicators and Reagents (Reagents)IBA 06/15/1992 - "We used this SCID mouse model of human pre-B ALL to evaluate and compare, in a total of 434 SCID mice, the antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin and cyclophosphamide (CPA) as individual reagents and as combined immunochemotherapeutic regimens. " Order ALL the reference details at left...
5.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/15/1992 - "We used this SCID mouse model of human pre-B ALL to evaluate and compare, in a total of 434 SCID mice, the antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin and cyclophosphamide (CPA) as individual reagents and as combined immunochemotherapeutic regimens. " Order ALL the reference details at left...
6.	pokeweed antiviral proteinIBA 05/01/1992 - "We used this SCID mouse model of aggressive human pre-B ALL to evaluate the in vivo antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin. " Order ALL the reference details at left...
7.	Transcription Factors (Transcription Factor)IBA 05/15/2007 - "Pbx1, a homeodomain transcription factor that was originally identified as the product of a proto-oncogene in acute pre-B-cell leukemia, is a global regulator of embryonic development. " 01/18/2007 - "Pre-B-cell leukemia transcription factor 1 (Pbx1) was one of the prominently suppressed genes. " 12/15/2006 - "These data suggest a unifying mechanism whereby PDX1, myeloid ecotropic viral insertion site (MEIS), and pre-B-cell leukemia transcription factor 1 (PBX) may regulate ductal and acinar lineage specification during pancreatic development. " 02/01/2003 - "Using gene expression microarray technology to examine the inhibitory effects of CDKIs, we observed a cellular gene, the pre-B-cell leukemia transcription factor 1 (Pbx1) gene, down-regulated by CDKI treatment. " 06/01/2000 - "Among the tested B cell-associated transcription factors, Pax5 and E47 genes were expressed in all pre-B ALL and B-CLL samples. " Order ALL the reference details at left...
8.	Phosphotransferases (Kinase)IBA 01/01/2005 - "In this study, we have made use of small molecular weight inhibitors and an established stromal cell-dependent pre-B-ALL cell line, BLIN-2, to investigate the role of the MAP kinase, PI3K/Akt, JAK/STAT and mTOR pathways in the promotion of leukemic cell growth in the presence of stromal cell support. " 03/01/1992 - "We describe the molecular cloning of a receptor tyrosine kinase from a cell line (LK63) derived from a case of human pre-B-cell leukemia. " 02/01/1992 - "Insulin receptors in a pre-B-cell leukemia cell line (ACV) with t(1;19) were found to have 2-fold higher affinity for insulin, 5-fold higher basal and insulin-stimulated beta sub-unit autophosphorylation, and 2-fold higher basal and 4-fold higher insulin-stimulated beta sub-unit kinase activity on the synthetic peptide poly(Glu,Tyr), compared to receptors in a B-cell line (ADD) with normal karyotype from the same patient. " 03/31/1989 - "Insulin binding, insulin receptor kinase and cell surface immunofluorescence experiments all show that 697 cells express more surface insulin receptors than 207 cells, a line of pre-B ALL cells that lack the t(1;19). " 04/16/2004 - "Previous studies investigating the anti-viral mechanisms of several cyclin-dependent kinase inhibitors showed that the homeoproteins, pre B-cell leukemia transcription factor 1 (PBX1) and PBX-regulating protein-1 (PREP1), function as transcriptional activators of Moloney murine leukemia virus. " Order ALL the reference details at left...
9.	Interleukin-7 (Interleukin 7)IBA 04/01/1993 - "The presently described cell line should constitute a useful model of t(1;19) pre-B ALL and permit the study of IL-7 dependent signal transduction in human pre-B cells." 06/01/1999 - "The extent of survival of pre-B ALL cells supported by stromal cells and IL-3 and IL-7, correlated with the expression level of bcl-2 protein. " 07/01/1995 - "The present cell line should constitute a useful model of t(7;9) early pre-B ALL and allow investigation of the relationship between IL-4 and IL-7 negative signaling in leukemic B cell ontogeny." 06/01/1999 - "Addition of IL-3 to culture containing MS-10 cells enhanced the survival of pre-B ALL cells in all cases, whereas addition of IL-7 augmented the survival of pre-B ALL cells of some cases of stage III and all cases of stage IV. The survival of pre-B ALL cells was also supported by the conditioned media of MS-10 cells. " 06/01/1999 - "Neither IL-3, IL-7 nor IL-2 supported the survival of pre-B ALL cells. " Order ALL the reference details at left...
10.	AntigensIBA 11/01/2005 - "Since the early pre-B lymphoblast antigens were positive by the flow cytometry, the diagnosis was precursor B cell lymphoblastic lymphoma. " 06/01/1989 - "A CD10 (common ALL antigen)-negative, CD19-positive pre-pre-B ALL phenotype was observed in 24 infants. " 02/01/1988 - "In pre-B ALL, the stainings by anti common ALL antigen before and after cryopreservation were also very similar. " 01/01/1988 - "A prognostically favorable cytogenetic feature, hyperdiploidy greater than 50 chromosomes, was found in 33% of cases classified as common ALL antigen positive (CALLA+) early pre-B (common) ALL, in contrast to 18% of pre-B cases (P = .012), 5% of T cell cases (P less than .001), and none of the B cell cases (P less than .001) or cases of CALLA negative (CALLA-) early pre-B ALL (P = .002). " 12/01/1986 - "Loss of the common ALL antigen (CALLA) was a frequent change, occurring in 8 of the 51 cases initially classified as common or pre-B ALL. " Order ALL the reference details at left...

Therapies and Procedures

1.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 09/01/1994 - "A 41-year-old female patient with a pre-B ALL expressing 2 BCR/ABL transcripts e1/a2 and b2/a2 underwent autologous bone marrow transplantation (aBMT) with marrow grown in long-term culture (LTC) for consolidation of remission (CR). " 05/01/2006 - "An 18-month-old girl was diagnosed with pre-pre-B ALL/t(4;11) leukemia, which during the treatment and after matched bone marrow transplantation (BMT), underwent two consecutive switches from lymphoid to myeloid lineage and vice versa. " 05/01/1994 - "Twenty-two patients with high risk hematologic malignancies (13 c-ALL, two B-ALL/NHL, four T-ALL, two AML M2, one pre-pre B-ALL) entered a phase I/II trial with cyclic administration of low dose natural interleukin-2/recombinant interferon-gamma (nIL-2/rIFN-gamma) following autologous bone marrow transplantation (ABMT), in order to induce a cytotoxic antileukemic effect. " Order ALL the reference details at left...
2.	Intravenous Infusions 01/01/2006 - "This case report describes the use of Rituximab for in vivo purging (by intravenous infusion) in a 12 years old boy with second remission of pre-B ALL. " Order ALL the reference details at left...
3.	Drug Therapy (Chemotherapy) 07/01/2008 - "Herein, we describe a case of precursor B-cell lymphoblastic lymphoma of the ovary that was successfully treated with surgery and chemotherapy. " 12/01/1994 - "CONCLUSION: The t(1;19) and the der(19)t(1;19) identify a relatively homogeneous group of patients with pre-B ALL, who can be expected to respond similarly to intensive chemotherapy. " 04/20/1978 - "Pre-B-cell leukemias were readily responsive to chemotherapy. " 08/01/1990 - "In a more recent and more intensive chemotherapy program (Total Therapy study XI), neither the t(1;19) nor other chromosomal translocations has conferred an inferior outcome, suggesting that effective treatment can offset the negative impact of chromosomal rearrangements in cases of childhood pre-B ALL." 07/01/1999 - "PATIENTS AND METHODS: Twenty-one children (10 girls, 11 boys) with standard risk pre-B ALL treated with chemotherapy had serum insulin-like growth factor-I (IGF-I), serum IGF binding protein-3 (IGFBP-3) levels, and linear growth and weight data measured every 3 months during MT. " Order ALL the reference details at left...
4.	Immunotherapy 07/15/1997 - "These studies show that antigen-specific CTL can be generated from the bone marrow of patients with pre-B-cell leukemias and these findings should facilitate the design of adoptive T-cell-mediated immunotherapy trials for the treatment of patients with B-cell precursor malignancies." Order ALL the reference details at left...
5.	Transplants (Transplant) 04/01/2000 - "Post-transplant blood and bone marrow samples from 12 patients with pre-B-ALL were studied. " 11/01/1999 - "Transplants for AML in induction failure or pre-B ALL in untreated first relapse or CR2 had an intermediate outcome, with 5-year survival of 10-20%. " 02/27/2002 - "BACKGROUND: We report a liver transplant patient with Epstein-Barr virus-negative, precursor B cell lymphoblastic lymphoma diagnosed 6 months after transplantation. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 6 Outcomes
Top 200 Key Drugs and Biologics
Top 10 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>